Compare AstraZeneca plc (AZN) vs General Motors Company (GM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs General Motors Company — how do they compare? AstraZeneca plc trades at $166.68 (market cap $253.13B), while General Motors Company trades at $76.69 (market cap $69.31B). The key difference: AstraZeneca plc is far larger — about 3.7× General Motors Company's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | GM | |
|---|---|---|
Market Cap | $253.13B | $69.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $86.38 |
52-Week Low | $137.44 | $48.89 |
Enterprise Value | $279.37B | $172.65B |
Dividend Yield | 1.92% | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
General Motors (GM) trades at $76.72, down 1.45% on the day, with a bearish technical signal from moving averages. The company shows strong cash flow from operations at $26.87B for 2025 and has beaten earnings estimates for three consecutive quarters. Recent news highlights GM's strategic pivot into energy and domestic manufacturing expansion, supported by a 63% analyst buy rating. Valuation metrics include a P/E of 28 and P/S of 0.4, indicating potential value relative to sales.
GM's outlook is mixed: solid cash generation and analyst optimism (consensus target $102) contrast with declining net margins (1.38% in 2025) and rising debt-to-asset ratios (46.79% in 2024). Risks include competitive pressures and macroeconomic headwinds, but the stock offers upside if margin improvements and energy initiatives materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →
